Caredx reports inducement grant under nasdaq listing rule 5635(c)(4)

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ (“caredx” or the “company”)— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on april 7, 2025, caredx granted to jennifer foley, the company's newly appointed chief product officer, certain stock awards as an inducement material to ms.
CDNA Ratings Summary
CDNA Quant Ranking